Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results, Beats Expectations By $0.23 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23, Briefing.com reports. The company had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. The company’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same period last year, the firm posted ($1.40) EPS.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $152.33 on Friday. The stock has a market cap of $19.19 billion, a price-to-earnings ratio of -42.79 and a beta of 0.41. The firm’s fifty day moving average is $149.65 and its 200 day moving average is $165.14. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $218.88.

Wall Street Analyst Weigh In

ALNY has been the subject of several research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $235.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Cantor Fitzgerald restated a “neutral” rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Needham & Company LLC reiterated a “buy” rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Finally, Wells Fargo & Company reduced their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a report on Friday, February 16th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $215.88.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.